Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. Crl
  6. /
  7. Hikma Pharmaceuticals USA Inc.
CRL
•Hikma Pharmaceuticals USA Inc.

Hikma Pharmaceuticals USA Inc. – FDA CRL

Record Details

Hikma Pharmaceuticals USA Inc. received a Complete Response Letter (CRL) from the FDA regarding its New Drug Application (NDA) for naloxone nasal spray, 8 mg, submitted on April 30, 2019. The FDA determined the application could not be approved in its current form due to significant product quality and manufacturing control deficiencies, reviewed under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act.

Key product quality issues included inconsistencies in extractables studies, particularly regarding the maximum daily dose used for analytical evaluation thresholds, and missing supporting information. For leachables studies, the FDA disagreed with the stability testing design and required re-evaluation with different storage orientations or strong justification, along with clarification of evaluation threshold discrepancies. The agency also cited overly broad acceptance criteria for total impurities, a missing specification for a potential degradation impurity, and the need for more robust method validation data, including forced degradation studies and system suitability requirements. Furthermore, the structural assignment of an impurity required direct spectroscopic evidence.

Manufacturing deficiencies highlighted the need for revised commercial batch records and comprehensive leachable and extractable studies for all product-contact materials to ensure compliance with relevant standards and regulations. The FDA also mandated the establishment and justification of in-process controls for pH, viscosity, and density, along with revisions to yield reconciliation limits which were deemed inadequate for reflecting process performance, citing 21 CFR 211.103 and 211.186(b)(7).

To achieve approval, Hikma must address all identified issues by providing updated studies, revised specifications, complete method validation reports, and improved manufacturing controls in accordance with regulatory expectations.

Company
Hikma Pharmaceuticals USA Inc.
Product type
Drugs
Office
Office of Neuroscience
Person
  • — Jerald Andry, MS
View Company Profile

ID · 830344a3-afdc-4f95-b595-813aa987af98

Other documents for Hikma Pharmaceuticals USA Inc.
  • 483 - 2024-06-12June 12, 2024
  • 483 - 2023-11-03November 3, 2023
  • 483 - 2019-09-10September 10, 2019
  • CRL
  • CRL

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

KeyPedia

ChatGPT

Claude

Perplexity

Grok

Copilot

Document or profile

One record shows the event. A profile shows the pattern.

Buy this document for the source file and details behind this single event.

Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.

Explore Hikma Pharmaceuticals USA Inc.
KeyPedia
Regulatory Data Transformed
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@keypedia.com
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.